Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association

Jennifer L. Cook, Monica Colvin, Gary S. Francis, Kathleen L. Grady, Timothy M. Hoffman, Mariell Jessup, Ranjit John, Michael S. Kiernan, Judith E. Mitchell, Francis D. Pagani, Michael Petty, Pasala Ravichandran, Joseph G. Rogers, Marc J. Semigran, J. Matthew Toole

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Mechanical circulatory support (MCS) offers a surgical option for advanced heart failure when optimal medical therapy is inadequate. MCS therapy improves prognosis, functional status, and quality of life.1,2 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) tracks patient selection and outcomes for all implanted US Food and Drug Administration-approved MCS devices. From June 2006 until December 2014, 15 000 patients received MCS, and 2000 implantations are performed annually. One-year survival with current continuous-flow devices is reported to be 80%, and 2-year survival, 70%.3 In patients awaiting heart transplantation, MCS provides a bridge to transplantation, and for others who are ineligible for heart transplantation, MCS provides permanent support or destination therapy. Indications and absolute and relative contraindications to durable MCS are listed in Table 1.

Original languageEnglish (US)
Pages (from-to)e1145-e1158
JournalCirculation
Volume135
Issue number25
DOIs
StatePublished - Jun 20 2017

Fingerprint

Patient Care
Heart Transplantation
Equipment and Supplies
Survival
United States Food and Drug Administration
Patient Selection
Registries
Therapeutics
Heart Failure
Transplantation

Keywords

  • AHA Scientific Statements
  • ambulatory care
  • congestive heart failure
  • emergency care
  • emergency first responders
  • ventricular assist device

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Recommendations for the Use of Mechanical Circulatory Support : Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association. / Cook, Jennifer L.; Colvin, Monica; Francis, Gary S.; Grady, Kathleen L.; Hoffman, Timothy M.; Jessup, Mariell; John, Ranjit; Kiernan, Michael S.; Mitchell, Judith E.; Pagani, Francis D.; Petty, Michael; Ravichandran, Pasala; Rogers, Joseph G.; Semigran, Marc J.; Toole, J. Matthew.

In: Circulation, Vol. 135, No. 25, 20.06.2017, p. e1145-e1158.

Research output: Contribution to journalArticle

Cook, JL, Colvin, M, Francis, GS, Grady, KL, Hoffman, TM, Jessup, M, John, R, Kiernan, MS, Mitchell, JE, Pagani, FD, Petty, M, Ravichandran, P, Rogers, JG, Semigran, MJ & Toole, JM 2017, 'Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association', Circulation, vol. 135, no. 25, pp. e1145-e1158. https://doi.org/10.1161/CIR.0000000000000507
Cook, Jennifer L. ; Colvin, Monica ; Francis, Gary S. ; Grady, Kathleen L. ; Hoffman, Timothy M. ; Jessup, Mariell ; John, Ranjit ; Kiernan, Michael S. ; Mitchell, Judith E. ; Pagani, Francis D. ; Petty, Michael ; Ravichandran, Pasala ; Rogers, Joseph G. ; Semigran, Marc J. ; Toole, J. Matthew. / Recommendations for the Use of Mechanical Circulatory Support : Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association. In: Circulation. 2017 ; Vol. 135, No. 25. pp. e1145-e1158.
@article{7298eb371b8e43a2bde6c86f7b6e4048,
title = "Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association",
abstract = "Mechanical circulatory support (MCS) offers a surgical option for advanced heart failure when optimal medical therapy is inadequate. MCS therapy improves prognosis, functional status, and quality of life.1,2 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) tracks patient selection and outcomes for all implanted US Food and Drug Administration-approved MCS devices. From June 2006 until December 2014, 15 000 patients received MCS, and 2000 implantations are performed annually. One-year survival with current continuous-flow devices is reported to be 80{\%}, and 2-year survival, 70{\%}.3 In patients awaiting heart transplantation, MCS provides a bridge to transplantation, and for others who are ineligible for heart transplantation, MCS provides permanent support or destination therapy. Indications and absolute and relative contraindications to durable MCS are listed in Table 1.",
keywords = "AHA Scientific Statements, ambulatory care, congestive heart failure, emergency care, emergency first responders, ventricular assist device",
author = "Cook, {Jennifer L.} and Monica Colvin and Francis, {Gary S.} and Grady, {Kathleen L.} and Hoffman, {Timothy M.} and Mariell Jessup and Ranjit John and Kiernan, {Michael S.} and Mitchell, {Judith E.} and Pagani, {Francis D.} and Michael Petty and Pasala Ravichandran and Rogers, {Joseph G.} and Semigran, {Marc J.} and Toole, {J. Matthew}",
year = "2017",
month = "6",
day = "20",
doi = "10.1161/CIR.0000000000000507",
language = "English (US)",
volume = "135",
pages = "e1145--e1158",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "25",

}

TY - JOUR

T1 - Recommendations for the Use of Mechanical Circulatory Support

T2 - Ambulatory and Community Patient Care: A Scientific Statement from the American Heart Association

AU - Cook, Jennifer L.

AU - Colvin, Monica

AU - Francis, Gary S.

AU - Grady, Kathleen L.

AU - Hoffman, Timothy M.

AU - Jessup, Mariell

AU - John, Ranjit

AU - Kiernan, Michael S.

AU - Mitchell, Judith E.

AU - Pagani, Francis D.

AU - Petty, Michael

AU - Ravichandran, Pasala

AU - Rogers, Joseph G.

AU - Semigran, Marc J.

AU - Toole, J. Matthew

PY - 2017/6/20

Y1 - 2017/6/20

N2 - Mechanical circulatory support (MCS) offers a surgical option for advanced heart failure when optimal medical therapy is inadequate. MCS therapy improves prognosis, functional status, and quality of life.1,2 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) tracks patient selection and outcomes for all implanted US Food and Drug Administration-approved MCS devices. From June 2006 until December 2014, 15 000 patients received MCS, and 2000 implantations are performed annually. One-year survival with current continuous-flow devices is reported to be 80%, and 2-year survival, 70%.3 In patients awaiting heart transplantation, MCS provides a bridge to transplantation, and for others who are ineligible for heart transplantation, MCS provides permanent support or destination therapy. Indications and absolute and relative contraindications to durable MCS are listed in Table 1.

AB - Mechanical circulatory support (MCS) offers a surgical option for advanced heart failure when optimal medical therapy is inadequate. MCS therapy improves prognosis, functional status, and quality of life.1,2 The INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) tracks patient selection and outcomes for all implanted US Food and Drug Administration-approved MCS devices. From June 2006 until December 2014, 15 000 patients received MCS, and 2000 implantations are performed annually. One-year survival with current continuous-flow devices is reported to be 80%, and 2-year survival, 70%.3 In patients awaiting heart transplantation, MCS provides a bridge to transplantation, and for others who are ineligible for heart transplantation, MCS provides permanent support or destination therapy. Indications and absolute and relative contraindications to durable MCS are listed in Table 1.

KW - AHA Scientific Statements

KW - ambulatory care

KW - congestive heart failure

KW - emergency care

KW - emergency first responders

KW - ventricular assist device

UR - http://www.scopus.com/inward/record.url?scp=85020113658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020113658&partnerID=8YFLogxK

U2 - 10.1161/CIR.0000000000000507

DO - 10.1161/CIR.0000000000000507

M3 - Article

C2 - 28559233

AN - SCOPUS:85020113658

VL - 135

SP - e1145-e1158

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 25

ER -